Elicio Therapeutics, Inc. 8K

Elicio Therapeutics reported hypothesis-generating complete response data in metastatic KRAS-mutant pancreatic cancer following ELI‑002 7P and subsequent nivolumab-based therapy and outlined a planned Phase 1 combination trial in metastatic PDAC, contingent on funding.

Elicio Therapeutics furnished an investor presentation describing new translational and clinical observations from three metastatic KRAS-mutant pancreatic ductal adenocarcinoma (mPDAC) patients who, after prior treatment with its investigational off‑the‑shelf immunotherapy ELI-002 7P, subsequently achieved confirmed, durable complete radiographic, metabolic, and biomarker responses to nivolumab-based regimens despite having MSS/MMR‑proficient disease, and outlining a planned, capital‑efficient Phase 1 trial of ELI‑002 7P in combination with checkpoint inhibition and chemotherapy in first‑line and recurrent metastatic PDAC, subject to securing funding. The deck emphasizes hypothesis‑generating evidence that ELI‑002 7P may prime durable mKRAS‑specific and broader anti‑tumor T‑cell immunity that improves responsiveness to later chemo‑immunotherapy, compares these outcomes to historically low complete response rates in mPDAC across chemotherapy and immunotherapy regimens, and details the proposed Phase 1 design, key endpoints, and potential to inform subsequent metastatic and adjuvant Phase 3 development.

Filing Facts

CIK

1601485

Ticker

-

Form

8K

Source Type

sec

Accession

0001601485-26-000050

Alert Tier

6